<DOC>
	<DOCNO>NCT02415829</DOCNO>
	<brief_summary>The study aim identify efficacy safety capecitabine plus oxaliplatin ( XELOX ) patient local advanced colorectal cancer .</brief_summary>
	<brief_title>Efficacy Safety Oxaliplatin Combined With Capecitabine Neoadjuvant Chemotherapy Locally Advanced Colon Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Performance status ( ECOG ) 0~2 2 . Histologically confirm colon cancer . 3 . No prior treatment 4 . CTdefined T4 lymph nodepositive colon cancer 5 . Neutrophils ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , hemoglobin ≥ 8 g/dL Bilirubin level ≤ 1.0 x ULN 6 . AST ALT &lt; 1.5 x ULN 7 . Serum creatinine ≤ 1.0 x ULN 8 . Life expectancy ≥ 3 month 9 . Signed write informed consent 1 . Final stage cancer cachexia 2 . Allergy capecitabine oxaliplatin 3 . Any evidence extrahepatic metastasis and/or primary tumor recurrence 4 . Severe organ failure disease , include : clinically relevant coronary disease , cardiovascular disorder myocardial infarction within 12 month study entry , severe psychiatric illness , severe infection DIC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Neoajuvant chemotherapy</keyword>
</DOC>